Trials of a new drug combination to treat tuberculosis could cut the length of time patients have to take their medicine by a third.
Researchers at St George’s, University of London, hope that speeding up the treatment will help to reduce the 20 million cases of the disease that exist globally – many caused by patients abandoning their medication halfway through because of the long trek to a treatment centre or at the first signs it is working.
In the four-year trial, a high dose of antibiotic drug rifapentine and a broad-spectrum antibiotic, called moxifloxacin, will be given once a week to patients with pulmonary TB in Mozambique, Zambia, Zimbabwe and South Africa. Both rifapentine and moxifloxacin are already used in the treatment of TB, though not in combination. It is hoped that RIFAQUIN, as the new combination is called, will cut the treatment time from six to four months.
Dr. Stanley Mungofa, the Head of the Harare City Health Department, Harare, Zimbabwe, and an investigator in the RIFAQUIN trial, said: “TB treatment just like treatment for chronic diseases tends to be difficult for both the patient and the health system given the fact that when patients feel better they confuse better for cure and abandon their treatment.
“If treatment becomes shorter there is a better chance of them finishing their medication and being cured.”
The trial will start in July 2007and is being carried out by INTERTB, an international consortium of scientists coordinated by Dr Amina Jindani at St George’s, University of London. Professor Denis Mitchison, who successfully pioneered the reduction of treatment from 18 to six months, and Dr Tom Harrison are also on the St George’s INTERTB team.
Dr Jindani said: ‘The development of a new anti-tuberculosis drug could take 15 years and the cost estimated by the Stop TB partnership is almost 5 billion US dollars. By testing a new combination of drugs we already use we can cut that development time by 10 years at a far lower cost.’
The trial has already attracted grants of €4,281,991 (£2.855million) from the European & Developing Countries Clinical Trials Partnership (EDCTP) and a further £200,000 from the Wellcome Trust.
INTERTB is organising a one-day meeting to discuss the contribution of UK researchers to reduce TB treatment duration. The meeting will be held at St. George’s, University of London, on Thursday 22nd March, 2007 and will be attended by researchers in the United Kingdom as well as donor agencies, NGOs and members of the All Party Parliamentary Working Group on TB.
Tamsin Starr | alfa
Hot cars can hit deadly temperatures in as little as one hour
24.05.2018 | Arizona State University
3D images of cancer cells in the body: Medical physicists from Halle present new method
16.05.2018 | Martin-Luther-Universität Halle-Wittenberg
The more electronics steer, accelerate and brake cars, the more important it is to protect them against cyber-attacks. That is why 15 partners from industry and academia will work together over the next three years on new approaches to IT security in self-driving cars. The joint project goes by the name Security For Connected, Autonomous Cars (SecForCARs) and has funding of €7.2 million from the German Federal Ministry of Education and Research. Infineon is leading the project.
Vehicles already offer diverse communication interfaces and more and more automated functions, such as distance and lane-keeping assist systems. At the same...
A research team led by physicists at the Technical University of Munich (TUM) has developed molecular nanoswitches that can be toggled between two structurally different states using an applied voltage. They can serve as the basis for a pioneering class of devices that could replace silicon-based components with organic molecules.
The development of new electronic technologies drives the incessant reduction of functional component sizes. In the context of an international collaborative...
At the LASYS 2018, from June 5th to 7th, the Laser Zentrum Hannover e.V. (LZH) will be showcasing processes for the laser material processing of tomorrow in hall 4 at stand 4E75. With blown bomb shells the LZH will present first results of a research project on civil security.
At this year's LASYS, the LZH will exhibit light-based processes such as cutting, welding, ablation and structuring as well as additive manufacturing for...
There are videos on the internet that can make one marvel at technology. For example, a smartphone is casually bent around the arm or a thin-film display is rolled in all directions and with almost every diameter. From the user's point of view, this looks fantastic. From a professional point of view, however, the question arises: Is that already possible?
At Display Week 2018, scientists from the Fraunhofer Institute for Applied Polymer Research IAP will be demonstrating today’s technological possibilities and...
So-called quantum many-body scars allow quantum systems to stay out of equilibrium much longer, explaining experiment | Study published in Nature Physics
Recently, researchers from Harvard and MIT succeeded in trapping a record 53 atoms and individually controlling their quantum state, realizing what is called a...
25.05.2018 | Event News
02.05.2018 | Event News
13.04.2018 | Event News
25.05.2018 | Event News
25.05.2018 | Machine Engineering
25.05.2018 | Life Sciences